LPL Receptor

SLF1081851 is a selective inhibitor of Spns2, effectively inhibiting sphingosine-1-phosphate (S1P) release with an IC50 of 1.93 μM. This compound is crucial for studying developmental processes and immune responses, making it a valuable tool in research focused on modulating these biological pathways. Its ability to target Spns2 provides insight into the mechanisms regulating S1P availability and its subsequent effects on cell signaling and function.

SLF80821178 is a potent inhibitor of the Sphingosine-1-Phosphate Transporter (Spns2), exhibiting an IC50 of 51 nM for the inhibition of S1P release in HeLa cells. This orally active compound demonstrates a half-life of 2.4 hours in mouse models. Research applications include the investigation of sphingosine metabolism and transport in cellular signaling pathways.

S1PR1 modulator 1 is a selective inhibitor of the S1PR1 receptor, demonstrating a pIC50 of 7.6 and exhibiting greater than 40-fold selectivity over S1PR2 and over 80-fold selectivity over S1PR3 and S1PR4. This compound is valuable for investigating S1PR1-mediated signaling pathways and its role in various biological processes, including immune response regulation and cardiovascular function. Its specificity makes it an important tool for research applications focused on the modulation of S1P receptor activity in disease models.

CRT0273750 is an inhibitor of autotaxin (ATX), which plays a crucial role in the modulation of lysophosphatidic acid (LPA) levels, exhibiting an IC50 of 0.014 μM. This compound is valuable in the study of ATX/LPA-dependent cancer models, contributing to research on tumor progression and metastasis. Its specificity for ATX provides a useful tool for elucidating the underlying mechanisms of LPA-mediated signaling pathways in various biological contexts.

SLB1122168 is a selective inhibitor of Spns2 that significantly impairs the release of sphingosine-1-phosphate (S1P) with an IC50 of 94 nM. This compound is useful for investigating the role of S1P in various biological processes, including immune response and cardiovascular regulation. Its application in research can help elucidate the mechanisms underlying Spns2 activity and S1P signaling pathways.

S1PL-IN-1 is a selective sphingosine-1-phosphate lyase inhibitor with an IC50 of 210 nM. This compound exhibits potential in modulating S1P signaling pathways and may serve as a Smoothened receptor antagonist with an IC50 of 440 nM. S1PL-IN-1 is primarily utilized in the study of experimental autoimmune encephalomyelitis and related neurological disorders. Its capacity to influence sphingolipid metabolism makes it a valuable tool for research into neuroinflammatory conditions.

SLF1081851 TFA is a selective inhibitor of Spns2, effectively inhibiting sphingosine-1-phosphate (S1P) release with an IC50 of 1.93 μM. This compound is instrumental in studies related to developmental biology and immune regulation. Its ability to modulate S1P levels makes it a valuable tool for investigating pathways involved in immune responses and developmental processes.

SLF80821178 hydrochloride is a selective inhibitor of the sphingosine-1-phosphate transporter (Spns2), effectively reducing sphingosine-1-phosphate (S1P) release in HeLa cells with an IC50 value of 51 nM. This compound demonstrates the capability to decrease circulating lymphocyte levels in mice without altering plasma S1P concentrations, making it a valuable tool for studying immune response and signaling pathways. Research applications include investigations into lymphocyte trafficking and potential therapeutic strategies targeting sphingosine metabolism.

SLF1081851 hydrochloride is a potent inhibitor of Spns2, effectively suppressing sphingosine-1-phosphate (S1P) release with an IC50 of 1.93 μM. This compound is significant for research into immune system development and related biological processes. It serves as a valuable tool for investigating the role of S1P in various cellular functions and pathological conditions.

SPL-IN-1 is a selective sphingosine-1-phosphate lyase inhibitor that targets the SPL enzyme. It has demonstrated significant biological activity in modulating sphingolipid metabolism and influencing cellular signaling pathways. This compound is valuable for research applications involving inflammation, cancer progression, and other diseases associated with sphingosine-1-phosphate signaling dysregulation.

Spns2-IN-3 is a selective SPNS2 inhibitor that targets sphingolipid metabolism. This compound exhibits significant biological activity in modulating sphingolipid pathways, making it crucial for research applications involving cellular signaling and lipid biology. Its unique structure may facilitate the development of drug carriers, enhancing the delivery and penetration of therapeutic molecules across biological membranes, particularly in dermatological settings.